PMID- 31766968
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Jul
TI  - Successful rechallenge of rituximab following severe rituximab-induced acute 
      thrombocytopenia in a patient with splenic marginal zone lymphoma.
PG  - 1248-1253
LID - 10.1177/1078155219890023 [doi]
AB  - Rituximab-induced acute thrombocytopenia (RIAT) is a relatively rare complication 
      of rituximab treatment that has been infrequently reported in a number of 
      patients with malignant lymphoma. Most commonly encountered in mantle cell 
      lymphoma, the extent to which RIAT occurs in splenic marginal zone lymphoma is 
      unknown. In this report, we describe a case of RIAT in a patient with splenic 
      marginal zone lymphoma. Rituximab was safely rechallenged with increased 
      premedications and slowed infusion rate. While the exact mechanism of this 
      phenomenon has yet to be elucidated, diligent monitoring of platelet counts 
      following rituximab infusion can be considered in high-risk patients to avoid 
      potential adverse events. Split dose rituximab for high-risk patients may provide 
      an alternative approach to improve patient safety.
FAU - Robinson, Adam C
AU  - Robinson AC
AD  - Department of Pharmacy Services, Barnes-Jewish Hospital, St. Louis, MO, USA.
FAU - Nachar, Victoria R
AU  - Nachar VR
AUID- ORCID: 0000-0002-5906-4733
AD  - Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, 
      University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20191125
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/administration & dosage/*adverse effects
MH  - Humans
MH  - Infusions, Parenteral
MH  - Lymphoma, B-Cell, Marginal Zone/diagnosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Rituximab/administration & dosage/*adverse effects
MH  - *Severity of Illness Index
MH  - Splenic Neoplasms/diagnosis/*drug therapy
MH  - Thrombocytopenia/*chemically induced/diagnosis/drug therapy
OTO - NOTNLM
OT  - RIAT
OT  - rituximab
OT  - splenic marginal zone lymphoma
OT  - thrombocytopenia
EDAT- 2019/11/27 06:00
MHDA- 2020/10/27 06:00
CRDT- 2019/11/27 06:00
PHST- 2019/11/27 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2019/11/27 06:00 [entrez]
AID - 10.1177/1078155219890023 [doi]
PST - ppublish
SO  - J Oncol Pharm Pract. 2020 Jul;26(5):1248-1253. doi: 10.1177/1078155219890023. 
      Epub 2019 Nov 25.